Company Filing History:
2 out of 29 
1 out of 4,447 
Years Active: 1991-1992
Title: The Innovative Journey of Richard M Bartholomew: Pioneering Advances in Antibody Research
Introduction: Richard M Bartholomew, a distinguished inventor based in San Diego, CA, USA, has made significant contributions to the field of biotechnology with his groundbreaking work in antibody research. With a total of 2 patents to his name, Bartholomew's innovative methods have revolutionized the production and efficacy of monoclonal antibodies.
Latest Patents:
1. Method for the reduction of heterogeneity of monoclonal antibodies: Bartholomew's method involves incubating heterogeneous antibodies at low pH to convert them into substantially homogeneous forms. This novel approach, which can also utilize ascites fluid or carboxypeptidase, allows for the purification of homogeneous antibodies in high yield.
2. Non-covalent antibody-anthracycline immunocomplexes: Bartholomew's composition comprises a non-covalent immunocomplex of an anthracycline agent and an antibody selected to enhance the cytotoxicity of the anthracycline agent. This innovation enhances the efficacy of anthracyclines as anti-tumor agents for in vivo therapy.
Career Highlights: Bartholomew's exceptional career includes roles at Hybritech Incorporated and Eli Lilly and Company, where he honed his skills and expertise in the field of biotechnology. His innovative approaches to antibody research have paved the way for advancements in therapeutic treatments and medical interventions.
Collaborations: Throughout his career, Bartholomew has collaborated with esteemed colleagues such as James P McDonough and Thomas C Furman. These collaborations have led to the development of pioneering techniques and methodologies in the production and utilization of monoclonal antibodies.
Conclusion: Richard M Bartholomew's innovative spirit and dedication to advancing antibody research have positioned him as a trailblazer in the field of biotechnology. His patents and contributions continue to shape the landscape of biomedical innovation, offering new possibilities for the development of novel therapeutic solutions and improved patient outcomes.